IL-1RAcP Inhibitors
IL-1RAcP inhibitors encompass a diverse array of chemicals that target IL-1 signaling pathways, either directly or indirectly influencing IL-1RAcP function. Among these inhibitors, BX-795 and Pellino3 Inhibitor act as direct inhibitors, affecting IL-1RAcP-associated signaling cascades. BX-795 targets TAK1, disrupting the activation of MAPK and NF-κB pathways downstream of IL-1 signaling. Pellino3 Inhibitor specifically targets Pellino3, leading to the downregulation of IL-1RAcP-mediated cellular responses. Triptolide, JSH-23, Bay 11-7082, TPCA-1, BAY 61-3606, and BIRB 796 act as indirect inhibitors by modulating the NF-κB pathway. Triptolide inhibits the nuclear translocation of NF-κB, influencing IL-1RAcP-mediated cellular responses. JSH-23 and Bay 11-7082 specifically target the NF-κB pathway, disrupting the downstream events of IL-1 signaling. TPCA-1 inhibits IKK-2, a kinase involved in the NF-κB pathway, leading to the modulation of IL-1RAcP function. BAY 61-3606 directly inhibits Syk, impacting cellular responses associated with IL-1RAcP activation. BIRB 796 targets p38 MAPK, a kinase associated with IL-1 signaling, influencing IL-1RAcP-mediated cellular responses.
TAK-242 and NF-κB Activation Inhibitor IV act as direct and indirect inhibitors, respectively, affecting IL-1RAcP by targeting TLR4 and inhibiting the activation of NF-κB. These inhibitors disrupt downstream signaling events in IL-1 signaling, leading to the modulation of IL-1RAcP function. IRAQ Inhibitor and SB 203580 are direct inhibitors of IL-1RAcP-associated signaling cascades. IRAK Inhibitor specifically targets interleukin-1 receptor-associated kinase (IRAK), disrupting the interaction between IL-1RAcP and downstream signaling partners. SB 203580 directly inhibits p38 MAPK, influencing cellular responses associated with IL-1RAcP activation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
BX 795 | 702675-74-9 | sc-281689 sc-281689A sc-281689C sc-281689B sc-281689D sc-281689E | 2 mg 5 mg 10 mg 25 mg 50 mg 100 mg | $219.00 $273.00 $331.00 $495.00 $882.00 $1489.00 | 5 | |
BX-795 is a direct inhibitor of TAK1, a kinase involved in IL-1 signaling. By inhibiting TAK1, BX-795 disrupts downstream signaling pathways, leading to the modulation of IL-1RAcP function. TAK1 inhibition can hinder the activation of MAPK and NF-κB pathways, influencing IL-1RAcP-mediated cellular responses. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $90.00 $204.00 | 13 | |
Triptolide acts as an indirect inhibitor of IL-1RAcP by targeting the NF-κB pathway. It inhibits the nuclear translocation of NF-κB, a downstream effector in IL-1 signaling. By influencing the NF-κB pathway, triptolide indirectly modulates IL-1RAcP-mediated cellular responses, impacting the inflammatory and immune processes associated with IL-1 signaling. | ||||||
NFκB Activation Inhibitor II, JSH-23 | 749886-87-1 | sc-222061 sc-222061C sc-222061A sc-222061B | 5 mg 10 mg 50 mg 100 mg | $214.00 $257.00 $1775.00 $2003.00 | 34 | |
JSH-23 is a specific inhibitor of the NF-κB pathway, indirectly affecting IL-1RAcP signaling. By inhibiting the nuclear translocation of NF-κB, JSH-23 disrupts the downstream events of IL-1 signaling, leading to the modulation of IL-1RAcP function and influencing cellular responses associated with IL-1RAcP activation. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
Bay 11-7082 is an indirect inhibitor of IL-1RAcP, targeting the NF-κB pathway. By preventing the activation of NF-κB, Bay 11-7082 disrupts the downstream events of IL-1 signaling. This inhibition influences IL-1RAcP function, leading to the modulation of cellular responses associated with IL-1RAcP activation and impacting the inflammatory and immune processes regulated by IL-1 signaling. | ||||||
IKK-2 Inhibitor IV | 507475-17-4 | sc-203083 | 500 µg | $133.00 | 12 | |
TPCA-1 is a specific inhibitor of IKK-2, a kinase involved in the NF-κB pathway. By inhibiting IKK-2, TPCA-1 disrupts the activation of NF-κB and downstream signaling events in IL-1 signaling. This indirect inhibition influences IL-1RAcP function, modulating cellular responses associated with IL-1RAcP activation and impacting the inflammatory and immune processes regulated by IL-1 signaling. | ||||||
BAY 61-3606 | sc-507485 | 2 mg | $345.00 | 1 | ||
BAY 61-3606 is a specific inhibitor of Syk, a kinase involved in IL-1 signaling. By inhibiting Syk, BAY 61-3606 disrupts the downstream signaling cascades, leading to the modulation of IL-1RAcP function. Syk inhibition can affect cellular responses associated with IL-1RAcP activation, influencing the inflammatory and immune processes regulated by IL-1 signaling. | ||||||
Doramapimod | 285983-48-4 | sc-300502 sc-300502A sc-300502B | 25 mg 50 mg 100 mg | $149.00 $281.00 $459.00 | 2 | |
BIRB 796 is a direct inhibitor of p38 MAPK, a kinase associated with IL-1 signaling. By inhibiting p38 MAPK, BIRB 796 disrupts the downstream signaling events, leading to the modulation of IL-1RAcP function. p38 MAPK inhibition influences cellular responses associated with IL-1RAcP activation, impacting the inflammatory and immune processes regulated by IL-1 signaling. | ||||||
Resatorvid | 243984-11-4 | sc-476758 | 5 mg | $367.00 | ||
TAK-242 is a direct inhibitor of TLR4, a receptor involved in IL-1 signaling. By inhibiting TLR4, TAK-242 disrupts the downstream events in IL-1 signaling, leading to the modulation of IL-1RAcP function. TLR4 inhibition can influence cellular responses associated with IL-1RAcP activation, impacting the inflammatory and immune processes regulated by IL-1 signaling. | ||||||
CAY10512 | 139141-12-1 | sc-205237 sc-205237A | 10 mg 100 mg | $68.00 $550.00 | ||
This compound acts as an indirect inhibitor of IL-1RAcP by specifically inhibiting the activation of NF-κB. By preventing NF-κB activation, it disrupts the downstream signaling events in IL-1 signaling, leading to the modulation of IL-1RAcP function. Inhibition of NF-κB activation influences cellular responses associated with IL-1RAcP activation, impacting the inflammatory and immune processes regulated by IL-1 signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 is a direct inhibitor of p38 MAPK, a kinase associated with IL-1 signaling. By inhibiting p38 MAPK, SB 203580 disrupts the downstream signaling events, leading to the modulation of IL-1RAcP function. p38 MAPK inhibition influences cellular responses associated with IL-1RAcP activation, impacting the inflammatory and immune processes regulated by IL-1 signaling. | ||||||